Hainan Huluwa Pharmaceutical Group Co Ltd Total Liabilities
Hainan Huluwa Pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has total liabilities worth CN¥2.13 Billion CNY (≈ $311.18 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 605199 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
Total liabilities of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025. This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hainan Huluwa Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metropolitan Land Tbk
JK:MTLA
|
Indonesia | Rp2.24 Trillion |
|
Guangdong Dcenti Auto-Parts Stock Ltd Co
SHG:603335
|
China | CN¥903.09 Million |
|
Shenke Slide Bearing Corp
SHE:002633
|
China | CN¥374.40 Million |
|
All For One Steeb AG
F:A1OS
|
Germany | €301.06 Million |
|
Gospell Digital Technology Co Ltd
SHE:002848
|
China | CN¥390.53 Million |
|
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
|
USA | $10.71 Million |
|
Jerusalem
TA:JBNK
|
Israel | ILA21.45 Billion |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
USA | $10.15 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Hainan Huluwa Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Hainan Huluwa Pharmaceutical Group Co Lt's balance sheet.
Liquidity & Leverage Metrics
Hainan Huluwa Pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
Hainan Huluwa Pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Huluwa Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
The table below shows the annual total liabilities of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.14 Billion ≈ $313.87 Million |
-3.44% |
| 2024-12-31 | CN¥2.22 Billion ≈ $325.04 Million |
+16.84% |
| 2023-12-31 | CN¥1.90 Billion ≈ $278.20 Million |
+46.61% |
| 2022-12-31 | CN¥1.30 Billion ≈ $189.76 Million |
+56.16% |
| 2021-12-31 | CN¥830.41 Million ≈ $121.51 Million |
+37.33% |
| 2020-12-31 | CN¥604.68 Million ≈ $88.48 Million |
+36.60% |
| 2019-12-31 | CN¥442.67 Million ≈ $64.78 Million |
-9.17% |
| 2018-12-31 | CN¥487.37 Million ≈ $71.32 Million |
+6.92% |
| 2017-12-31 | CN¥455.83 Million ≈ $66.70 Million |
+11.93% |
| 2016-12-31 | CN¥407.26 Million ≈ $59.59 Million |
-- |
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceut… Read more